Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Operating Leases (2019 - 2026)

Wave Life Sciences (WVE) has disclosed Operating Leases for 8 consecutive years, with $7.4 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases fell 52.99% year-over-year to $7.4 million; the TTM value through Mar 2026 reached $7.4 million, down 52.99%, while the annual FY2025 figure was $9.4 million, 47.06% down from the prior year.
  • Operating Leases hit $7.4 million in Q1 2026 for Wave Life Sciences, down from $9.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $33.7 million in Q3 2022 and bottomed at $7.4 million in Q1 2026.
  • Average Operating Leases over 5 years is $20.8 million, with a median of $21.7 million recorded in 2024.
  • Year-over-year, Operating Leases surged 140.62% in 2023 and then crashed 52.99% in 2026.
  • Wave Life Sciences' Operating Leases stood at $32.1 million in 2022, then dropped by 20.9% to $25.4 million in 2023, then crashed by 30.07% to $17.8 million in 2024, then crashed by 47.06% to $9.4 million in 2025, then decreased by 21.46% to $7.4 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $7.4 million, $9.4 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.